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ABBREVIATIONS 
ReA : Reactive arthritis 
USpa : Undifferentiated Spondyloartropathy 
SPA : Spondyloarthropathy 
CRP : C reactive protein 
ESR : Erythrocyte sedimentation rate 
MOMP : Membrane outer membrane protein 
LPS : Lipopolysaccharide 
YOP : Yersinia outermembrane protein  
YAD                                Yersinia adherence protein 
Ct  : Chlamydia trachomatis 
Cpn  : Chlamydia pneumonia 
PCR : Polymerase chain reaction 
DNA : Deoxyibonucleic acid 
ELISA : Enzyme linked immunosorbent assay    
TNF : Tumour necrosis factor 
IL : Interleukin 
HLA : Human Leukocyte antigen 
PBS : Phosphate buffer saline 
TMB : Tetramethyl benzidine 
DMARD : Disease modifying anti-rheumatic drugs 
XLD : Xylose lysine deoxycholate. 
IBA : Inflammatory back ache 
CT                         :        Computerised Tomogram 
CREA : Chronic Reactive Arthritis  
MVPS : Mitral Valve Prolapse Syndrome 
LVH : Left Ventricular Hypertrophy 
AML : Anterior Mitral Leaflet 
PML : Posterior Mitral Leaflet 
OD : Odds Ratio 
B/L : Bilateral 
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INTRODUCTION 
Reactive arthritis (ReA) is a spondyloarthropathic group of disorders 
characterized by inflammation of the joints occurring either after a 
genitourinary or gastrointestinal infection. Its is a sterile synovitis associated 
with infection at a distant site without evidence of sepsis  at the affected joint 
and often associated with  urethritis, conjunctivitis and occurrence of other 
extraarticular manifestations. Time interval between the onset of infection and 
joint symptoms should be between 1 week to a   of maximum 4 weeks . 
Clinical features are classically characterized by axial arthritis, 
oligoarthritis and enthesitis accompanied by extraarticular manifestations. 
Musculoskeletal symptoms are often acute associated with systemic features 
such as fatigue, weight loss and fever. Extraarticular symptoms include 
mucocutaneous, ocular and cardiac manifestations. Men and women are 
equally affected and the common age group is 20 to 40.Different bacterial 
species are associated with reactive arthritis.  Commonest enteric pathogens 
are Salmonella, Shigella, Campylobacter and Yersinia. Chlamydia trachomatis 
is the commonest genitourinary pathogen. 
Factors contributing to etiopathogenesis include alternation in cytokine 
profile leading to impaired elimination of microbes , persistence of the microbe 
and trafficking of their antigenic peptides to the joint leading to pathological 
immune response. Genetic factors play a role leading to susceptibility and 65-
85% of reactive arthritis patients are positive for HLA-B27 .The disease is more 
severe and chronic in patients positive for HLA-B27. 
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Diagnosis of Reactive arthritis is made on the basis of classification 
criteria and laboratory parameters. Treatment is rest , non-steroidal anti-
inflammatory drugs and intra-articular steroids. In chronic reactive arthritis 
DMARD therapy is indicated. Role of antibiotic treatment is controversial.  
Reactive arthritis is usually a self limiting disorder,  however 15-30% 
may progress to chronic reactive arthritis (>6 months).Prognosis is less 
favourable in patients with HLA-B27 positivity. 
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AIM AND OBJECTIVE  
1) To study the clinical features of Reactive arthritis . 
2) To study the outcome of Reactive arthritis.  
a. To study the association of disease activity of Reactive arthritis and 
its outcome .  
b. To correlate the association between  HLA B27 and the outcome of 
Reactive arthritis 
c. To correlate the  serum levels of  IL 17A levels and disease activity 
of Reactive arthritis. 
d. To study the radiological outcome of Reactive arthritis.  
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REVIEW OF LITERATURE 
Reactive arthritis(ReA) is an inflammatory arthritis which arises either 
after a gastrointestinal or genitourinary tract infection. It belongs to the 
spondyloarthropathy  group of disorders and displays a strong interplay 
between host and environment. Classic triad includes symptoms of urethra, 
conjunctiva and synovium. In general there are two forms of reactive arthritis 
post dysentery and post venereal.  
HISTORY 
Many people attribute that, the description of reactive arthritis was 
first  by Hans Reiter in 1916,1 when he described the clinical triad of arthritis, 
nongonococcal urethritis, and conjunctivitis in a German soldier after an  
episode of bloody diarrhea. The syndrome was also described by two French 
physicians Fiessinger and Leroy2 in the same year and hence Fiessinger-Leroy 
syndrome has also been used. But the description of reactive arthritis dates 
back to 460 B.C ,when Hippocrates wrote “A youth does not suffer from Gout 
until sexual intercourse.3‟‟ Christopher Columbus developed ReA in 1494, 
after a bout of dysentery4.Several cases were described in literature by many 
persons . Pierre van Forest‟s description of a case of „„secondary arthritis and 
urethritis‟‟ in 15075, Thomas Sydenham‟s association of arthritis with 
diarrhea in 16866, Stoll‟s documentation of arthritis following dysentery in 
17767, and Yvan‟s description of a French captain who developed 
“ophthalmia” and inflammatory arthritis primarily of the lower extremities 15 
days after a venereal infection8. The classic triad of ReA was first described 
in 1818 by Brodie9 .He documented  five patients who had triad of  urethritis, 
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arthritis, and conjunctivitis, and the second was in 1897 by Launoi‟s when he 
distinguished septic from aseptic arthritis10.In 1824, Cooper proposed the 
relationship between venereal infections and arthritis, predominantly of lower 
extremities11.In 1942 two researchers , Bauer and Engelmann from Harvard  
recognized the symptoms of ReA as a syndrome again. But in their literature 
review they found that this syndrome was already described by Hans Reiter in 
1916, so they coined the term as Reiter‟s syndrome11.A thorough search of 
history reveals that Sir Hans Reiter was the first to describe this syndrome to 
have an infectious etiology, though he described it due to spirochaetal 
infections (spirochetosis arthritica). Since Hans Reiter performed medical 
experiments on prisoners during the world war, people argued against using 
the term Reiter‟s syndrome. The term Reiter‟s syndrome is no longer used 
now. Many  clinicians are reluctant to diagnose Reiter‟s syndrome in the 
absence of  the complete triad of symptoms, thereby missing  a majority of 
cases. The term Reactive arthritis has now become the most appropriate 
terminology.  
Table-1: Proposed Criteria for Reactive Arthritis in  Literature 
Ahvonen 
et al  
1969 
Arthritis that develops soon after or during infection elsewhere 
in the body but in which the microorganism does not enter the 
joint cavity 
Olhagen,  
1980 
Uroarthritis and enteroarthritis are rheumatic conditions  
developing in association with urogenital and enteric infections, 
respectively. 
Willkens 
et al,  
1981 
Reiter‟s syndrome consists of an episode of peripheral arthritis 
of more than 1-month duration in association with urethritis 
and/or cervicitis. 
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Calin 
1984 
Seronegative asymmetric arthropathy (predominantly lower 
extremity) plus one or more of the following:  
 Urethritis / Cervicitis 
 Dysentery 
 Inflammatory eye disease 
 Mucocutaneous disease (balanitis, oral ulceration, 
keratoderma)and exclusion of other rheumatic diseases such 
as ankylosing spondylitis and psoriatic arthropathy 
Pacheco-
Tena et al, 
1999-  
Probable reactive arthritis 
 Musculoskeletal symptoms (arthritis, oligoarthritis, 
polyarthritis or arthropathy) 
 Clinical features of infectious disease (diarrhea or urethritis) 
but no bacterial  identification preceding musculoskeletal 
symptoms by 4 to 6 weeks 
Definite ReA triggered by bacteria 
 Bacterial identification of an infectious disease preceding 
musculoskeletal symptoms 
 Bacterial identification in a recent onset (4 to 6 weeks) 
episode of musculoskeletal symptoms 
 Bacteria associated undifferentiated oligoarthritis or 
spondyloarthritis 
Modified ACR criteria for Reactive Arthritis-2004 
Arthritis for longer than 1 month with uveitis or cervicitis . 
Arthritis for longer than 1 month and other, urethritis or cervicitis or 
bilateral conjunctivitis. 
Episode of arthritis and conjunctivitis. 
Episode of arthritis of more than 1 month, urethritis, and conjunctivitis. 
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For a definite diagnosis of Reactive arthritis,  evidence of Arthritis with 
urethritis or cervicitis need to be present. No need for laboratory 
confirmation. 
Third International Workshop diagnostic criteria for Reactive Arthritis –
1996 (European Criteria)12 
Typical peripheral arthritis 
 Predominantly lower limb, asymmetric oligoarthritis 
Plus 
 Evidence of preceding infection 
o Where clear clinical diarrhoea or urethritis within preceding four 
weeks, laboratory confirmation is desirable but not essential  
o Where no clear clinical infection, laboratory confirmat ion of 
infection is essential 
Exclusion Criteria 
Patients with other known causes of mono/oligoarthritis, such as other 
defined spondyloarthropathies, septic arthritis, crystal arthritis, Lyme disease, 
and streptococcal ReA, should be excluded. 
The diagnosis of ReA does not require the presence of HLA-B27 or 
extraarticular features of Reiter's syndrome (conjunctivitis, iritis, skin lesions, 
non-infectious urethritis, cardiac and neurological features) or typical  
spondyloarthropathic features (inflammatory back pain, alternating buttock 
pain, enthesitis, iritis) but these, if present, should be recorded . 
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Laboratory tests For preceding infection 
Stool culture 
Helpful if positive; should be routine if previous diarrhoea; stool 
culture in absence of diarrhoea rarely positive. 
Urethral culture 
Urethral culture often positive in absence of symptoms; need to 
interpret in light of local asymptomatic carriage rate. 
Urine/urethral PCR 
These tests can be used, where available, instead of urethral culture or 
urethral immunofluorescence for bacteria. 
Serology 
Chlamydial IgG is of no value because of  high prevalence in 
community. A rising titre of IgA antibodies is useful in presence of non-
specific urethritis history. 
 Yersinia, Salmonella, and Campylobacter antibodies by ELISA: IgG 
antibodies-a fourfold change in titre or a strongly raised titre (difficult to  
specify; depends on local situation); IgA or IgM antibodies -may be more 
specific; useful if >2 standard deviations above control populations . 
Haemagglutination (Widal) tests for Yersinia or Salmonella are 
specific for recent infection but insensitive, especially for Salmonella. 
Shigella serology is of no use because of cross reactivity with 
Escherichia coli. 
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The following tests should currently be regarded as research tools: 
Immunofluorescence  for bacteria in  synovium  and proliferation of 
synovial  lymphocytes 
These tests are labour intensive and technically difficult tests whose 
sensitivity and specificity is uncertain. They are unlikely ever to be suitable 
for routine diagnostic use. 
PCR for chlamydial DNA in the joint 
A  potentially valuable test which could be practicable for routine use. 
Its sensitivity and specificity are being further investigated. This approach 
cannot currently be used for enteric ReA because it is uncertain whether DNA 
from enteric organisms reaches the joint  
Preliminary Classification Criteria for Reactive Arthritis     Modified 
from Braun et al., 2000  
 Major criteria 
1) Arthritis, with 2 of 3 of the following findings 
a. Asymmetric 
b. Mono or oligoarthritis 
c. Affection predominantly in lower limbs 
2) Preceding symptomatic infection, with 1 or 2 of the following findings  
a. Enteritis (diarrhoea for at least 1 day, 3 days to 6 weeks before the 
onset of arthritis) 
b. Urethritis (dysuria or discharge for at least 1 day, 3 days to 6 weeks 
before the onset of arthritis) 
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Minor criteria, at least 1 of the following 
1) Evidence of triggering infection 
a. Positive nucleic acid amplification test in the morning urine or 
urethral/cervical swab for Chlamydia trachomatis  
b. Positive stool culture for enteric pathogens associated with ReA 
2) Evidence of persistent synovial infection (positive immunohistology or 
PCR for Chlamydia) 
Definition of reactive arthritis 
Definite ReA Both major criteria and a relevant minor criterion 
Probable ReA 1) Both major criteria, but no relevant minor criteria or  
2) Major criteria 1 and one or more of minor criteria  
Exclusion Criteria 
Other causes for acute arthritis  
EPIDEMIOLOGY 
The incidence and prevalence of ReA depends on the prevalence of 
causative pathogens and on the geographic region .Incidence is estimated to 
be 5 - 14/100,000 patients, aged 18 - 60 years
14
. It is more common in 
Caucasians affecting men and women equally. Most patients are aged 20- 40 
yrs
13
.A population based study in OREGON – MINNESOTA14 reported an 
incidence of  0.6 to 3.1 cases per 100,000, following documented enteric 
bacterial infections, range depending upon the organism.0-22% infected 
persons subsequently developed reactive arthritis following Yersinial 
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infection according to a study by M.Vasala et al on the frequency of reactive 
arthritis after Yersinia infection15.  A   study done by E.Collantes-et-al on the 
disease pattern of spondyloarthropathies in Spain suggested that 1.2-1.4%of 
the patient with spondyloarthropathy had reactive arthritis16. A recent 
epidemiological study by Buschiazzo, Emilio-et-al in Argentina informed that 
among 402 patients with spondyloarthropathy aged 38.3 - 58 years, 
6.2%patients had ReA17. 
HLA-B7 is found in 30-70% of patients with reactive arthritis. Patients 
with HLA –B27 positivity had more extra-articular manifestations and more 
commonly progressed to chronic stage18. 
TRIGERRING MICROBES 
Bacteria associated with the development of reactive arthritis.  
Enteric infections 
Salmonella 
Various serovars 
Shigella 
S. flexneri 
S. dysenteriae 
S. sonnei 
Yersinia 
Y. enterocolitica (especially O:3 and O:9) 
Y. pseudotuberculosis 
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Campylobacter 
C. jejuni 
C. coli 
Clostridium difficile 
Escherichia coli 
Diarrhogenic strains 
Urogenital infections 
Chlamydia trachomatis 
Ureaplasma urealyticum 
Mycoplasma genitaliuma 
Respiratory infections 
Chlamydia pneumoniae 
Group A beta-hemolytic Streptococcus 
Other infections 
Borrelia 
Brucella 
         Mycobacterium 
Staphylococcus 
Viruses  
Various parasites 
Ascaris 
Giardia lamblia 
Filarial worms ,Schistosoma , Strongyloides stercoralis and Taenia 
saginata. 
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Though different bacterial species are associated with reactive arthritis, 
the classical enteric pathogens involved in the trigerring of reactive arthritis 
belong to Salmonella, Shigella, Yersiniae and Camplyobacter species. 
Chylamdia trachomatis is the most common urogenital pathogen.  
SALMONELLA  
It is a rod shaped motile bacterium most commonly involved in 
reactive arthritis. Salmonella typhimurium and Salmonella enteritidis are the 
subtypes commonly involved. Attack rates range from 6-30%.19,20 Causcians 
are more likely to develop reactive arthritis after Salmonellosis  than Asians. 
Children are less commonly affected than adults.  Buxton JA, et al, Hannu T, 
et al, Inman RD et al and Lee AT etal21-24 reported  that the attack rate of 
reactive arthritis ranged from 6-15% after an outbreak of Salmonella 
typhimurium in three different countries  The prevalence of HLA-B27 in these 
affected individuals ranged from 17-50%.After an outbreak of salmonella 
enterides in four different countries attack rate of ReA ranged from 7-
29%25,26.The prevalence of HLA-B27 was reported to be 33% in one of these 
outbreaks. A Denmark based study by Schiellerup P-etal, compared different 
enteric pathogens in the trigerring of reactive arthritis and found that 
Salmonella was the second most common organism next to Campylobactrium 
and  second most common arthritogenic27 . Reactive arthritis was reported in 
12% of patients after an outbreak of Salmonella bovismorbificans28.  
SHIGELLA 
 The first bacteria implicated in the cause of reactive arthritis was 
Shigella 29. However it is a  rare cause of ReA in developed countries 30. It is 
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caused by all four species of Shigella such as Shigellla sonnei, Shigella 
flexneri, Shigella dysenteriae and Shigella boydi of which Shigella flexneri 
and Shigella dysenteriae are the common organisms implicated. Shigella 
sonnei is a rare cause31.DNA of Shigella have been demonstrated in the 
synovial tissue of patients with ReA.  A study from Finland in 2005 revealed 
cases of reactive arthritis due to Shigella in which Shigella sonnei was the 
most common cause31.The attack rate of reactive arthritis in this study was 
7%.36% were HLA-B27 positive among those who developed reactive 
arthritis in this study.  
CAMPYLOBACTER JEJUNI 
ReA is caused both by Campylobacter jejuni and Campylobacter coli. 
It usually causes mild arthritis, either oligoarthritis or polyarthritis. 
Inflammatory back pain is uncommon compared to other types of reactive 
arthritis. A Finland based study in 2002 by Hannu T et al found that 7% of the 
campylobacter positive stool culture positive patients developed reactive 
arthritis32.In their study they could not find an association with HLA B27. A  
review study  by Pope JE et al suggested that the attack rate of  ReA after 
campylobacter jejuni infection is 1-5%. It does not have a significant 
association with HLA-B2733. 
YERSINIA 
Among the three species of Yersinia,only Yersinia enterocolitica and 
Yersinia pseudotuberculosis have been implicated in the causation of reactive 
arthritis. Compared to other organisms in the etiology of reactive arthritis 
Yersinia is very arthritogenic. A DENMARK study suggested that it is the 
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most common organism causing reactive arthritis 27.Yersinia 
pseudotuberculosis outbreak occured in two different places in 1998, one at 
Finland due to serovar 0:3 and the other at Canada due to serovar 1b and the 
joint symptoms occured subsequently in 12% of these affected individuals .34,35 
CHLAMYDIA 
Chlamydia trachomatis is the most common urogenital pathogen 
causing reactive arthritis. Chlamydia is the most common bacterium involved 
in sexually transmitted diseases and Trachomas. The ocular stains are A, B, C 
whereas the urogenital infections are caused by D-K serovars. In a review of 
Chlamydia induced reactive arthritis, contrary to the assumption that 
urogenital   serovars  are the ones to be seen in synovial tissue, it was the 
ocular serovar which was identified using the PCR technique
36
. If so, are the 
ocular serovars more arthritogenic than genital serovars? The question 
remains to be   answered. 
Possible explanations are 
1) The ability of the ocular serovar to disseminate is much more than the 
urogenital serovar 
2) If the initial inoculum of urogenital infection contains a small portion 
of ocular serovar the situation leads to an active arthritis episode.  
Chlamydial DNA has been demonstrated by PCR in the synovial tissue 
of patients with reactive arthritis.50% of patients develop reactive arthritis 
following symptomatic infection
37
.Chlamydia induced ReA is largely under 
diagnosed because most Chlamydial infections are asymptomatic and the 
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clinical triad is not expressed fully.In 2008, a study which analysed 
Chlamydial PCR positivity by Carter JD et al  in patients with 
undifferentiated spondyloarthropathy ,found that 62% of patients had PCR 
positivity suggesting,Chamydia could be an etiologic agent for 
undifferentiated SPA.
38
 
PATHOGENENSIS OF REACTIVE ARTHRITIS 
The pathogenesis of reactive arthritis is contributed by three factors. 
1) The presence of bacterial products in joints which is evident from the 
table below
39 
Bacterium 
Presence in joint of bacterial products 
Antigens DNA RNA Culture 
C. trachomatis + + + ± 
Y. enterocolitica + + ND − 
Y. pseudotuberculosis + − + − 
S. flexneri and S. sonnei + + ND − 
ND-Not Done 
2) The host bacterial interactions  
3) Local immune response 
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The interaction between the bacterial products and the host immune 
system is shown below
39 
 
PATHOGENESIS OF ENTERIC REACTIVE ARTHRITIS 
In enteric form of ReA, the bacteria survive outside the synovium such 
as gut mucosa and lymphatics, from which it is carried to the synovium by 
monocytes  and macrophages  and binds to the synovial blood vessels and the 
bacterial products persist in the synovium and elicit an inflammatory 
response
40-42
. 
A Study conducted to study the pathogenic mechanism of enteri c 
pathogens  such as Salmonella, Shigella and Yersinia found that after 
invasion of synovial cells by these bacteria, they undergo slow metabolic 
activity leading to the disappearance of bacterial cytosol leaving only 
bacterial products.
43-44
 Survival of Yersinia is provided by many virulence 
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factors such as cytotoxin, invasin and adhesion .These factors prevent the 
microbiocidal action of neutrophils and its adhesion to host cells by 
adherence factors YOP B and D. A cationic protein 19kDa urease 3 subunit 
shown to induce arthritis in mice, sticks to the cartilage and elicits an 
inflammatory response. 14kDa ribosomal protein also plays an important role.   
Regarding Shigella it causes apoptosis of the invading cell, hence its 
DNA is rarely found in synovial cells except when it is encoded by plasmid  
such as PSD2 which is arthrogenic.
45,46 
PATHOGENESIS OF CHLAMYDIA INDUCED ARTHITIS 
Chlamydia trachomatis is an obligate intracellular parasite implicated 
and studied in reactive arthritis extensively. Newer developments in genetics 
and molecular biology have helped in understanding the pathogenesis of 
Chlamydia induced reactive arthritis. Following urogenital infections, the 
pathogenic substances are found in synovial fluid many years after initial 
infection. The organisms after entering into the synovial fluid reside in the 
monocytes, and display new characteristics quite different from their normal 
activity in urogenital tissues. 
Chlamydia reaches the joint either during bacteremia or by 
monocytes.
47
 Chlamydia has an elementary body. Initially, the extracellular 
form (elementary body) attaches itself to the host cell and when taken inside 
the cell, stays in the membrane bound vesicle, forming the inclusion body. 
This develops into an active form called the reticulate body. This reticulate 
body undergoes cycles again and almost 80% get back to their original 
elementary bodies, which are capable of infecting. The elementary bodies are 
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released by cell lysis or exocytosis. Such replications incite significant 
inflammatory responses inside the human body. Within the joint cavity factors 
such as decreased apoptosis of host cells or down regulation of antigen 
presentation leads to the persistence of infection.
48,49
 Chlamydia survive 
within the synovial tissue rather than fluid in an altered elementary form 
leading to escape from immune surveillance. It also  upregulates HSP 60 
protein which is immunogenic. Studies have found the presence of three open 
reading frames coding heat shock protein HSP 60, Ct 110, Ct604 and Ct755.  
Of the three frames Ct604 is increased in persistent inflammatory models and 
Ct 755 is reduced
50
.Chlamydia also induces upregulation of proinflammatory 
cytokines such as IL1,IL6 and TNF α.21,22 The major target antigen in 
Chlamydia induced reactive arthritis is a 57 kDa heat shock protein. Further 
studies of the same has found no epitope recognition or cross reactivity. Other 
antigenic targets recognized are 18kDa histone protein and a 30 kDa antigen. 
Their  relevance has not been fully studied.  In Chlamydia induced urethritis, 
Outer Membrane Protein (OMP)of Chlamydia has been found to have a 
pathgenetic role. However  this OMP is not found in increased levels in joints 
of patients with reactive arthritis. This suggests that different immunogenetic 
responses happen in reactive arthritis.  
HLA B27  
HLA B27 is a Major Histocompatability Complex (MHC-I) molecule, 
formed in endoplasmic reticulum as a glycoprotein. It contains the heavy 
chain, β2 microglobulin and an aminoacid peptide. After synthesis,  the heavy 
chain undergoes glycosylation, it binds to β2 microglobulin and get 
chaperoned to form a heterodimer. It interacts with tapasin, calreticulin and 
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Erp57. A stable heavy chain – β2 microglobulin complex is needed for 
trafficking of signals to the cell surface achieved with help from 
chaperones.
51
 However HLA B27 is characterized by two unusual properties. 
The folding rate of this molecule is very slow allowing the formation of 
unstable and misfolded molecules and forms aberrant disulphide bonded 
dimers.
52
 B pocket of MHC class I molecule plays an important role in 
selection of peptides. It is the composition of B pocket which plays an 
important role in folding of HLA B27. Mutations in the B pocket and an 
unpaired cysteine residue at 67 allows the dimerisation of HLA B27.
53,54
 The 
aminoacids allowing the dimerisation of HLA B27 are present in almost all 
cases of reactive arthritis with HLA B27 positivity suggesting that they play a 
dynamic role in its pathogenesis as well. 
 
Accumulation of misfolded peptides evokes endoplasmic reticulum 
stress response, an Unfolded Protein Response (UPR). This unfolded protein 
response upregulates chaperones and improves the folding capacity of 
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endoplasmic reticulum. This applies to misfolded HLA B 27, evoking a stress 
response and in turn an inflammatory reaction also.  
ROLE OF HLA B27   IN THE PATHOGENENSIS OF 
REACTIVE ARTHRITIS 
HLA-B27 is composed of  25 glycoproteins (2701-2725).It belongs to 
MHC Class I molecule, the function of which is antigenic presentation to CD 
8+ cytotoxic T cells. HLA B27  has the strongest genetic association with 
reactive arthritis .The prevalence of reactive arthritis is five times more in 
patients with HLA B 27 positivity. After the role of HLA B27 has been 
identified in Ankylosing spondylitis, its role in Reactive arthritis has also 
been studied extensively. Published data analysis from Gambia suggested that 
not all subtypes of HLA B27 predispose to spondyloarthropathy. HLA-B2703 
is not associated with any of the spondyloarthropathies.  
 HLA-B2705 subtype was associated with Ankylosing spondylitis and 
reactive arthritis in the European population. HLA-B2706, found in Thailand, 
has not been described in association with AS, but this again may be due to 
any other reason as the population is not susceptible for reactive arthritis. T 
cell receptor and other co-transporters have not been identified in the 
pathogenesis of reactive arthritis. Apart   from HLA B27, MHC class II allele 
could also be associated. Though there are various explanations for 
association of HLA B27, none has been universally accepted. In   AS, more 
than   90% of the patients are HLA B27 positive, whereas the proportion is 
not so high in reactive arthritis.  
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The frequency of HLA B27 positivity is high in hospital admissions 
with reactive arthritis suggesting the fact that its association increases the 
disease severity and   chronicity  rather than being an inciting feature itself.  
Its positivity is also associated with iritis, sacroilitis and enthesitis .Inman et 
al suggested that HLAB27 positive cell lines are resistant to invasion by 
Salmonella and Yersinia, hence acute synovitis is rare.  
The most popular theory associating reactive arthritis with HLA B27 is 
the   arthritogenic peptide theory. Accordingly, HLA B27 which is expressed 
in MHC I cells, presents an arthritis inducing peptide to CD8+ cytotoxic T 
cells. The peptide is usually derived from the infecting bacterium and in 
chronic cases this may be incited by an autoantigen.  Bowness  identified  60 
peptides associated with Chlamydia which will bind HLA B27 and simulate 
an arthritic attack, one of which is HSP 70(heat shock protein)
55
. Marker et al 
has identified bacteria specific, HLA-B27 restricted CD8+ T cell clones from 
the synovial fluid of patients with enteric reactive arthritis . 
56
. 
 Mouse models developed by Hammer gave us newer insights on the 
arthritogenic peptide theory in which, neither mouse in pathogen free 
environment failed to develop arthritis  even with HLA B27 positivity
57
 nor   
do nude mice without T cells, suggesting the need for T cells in the 
pathogenesis of reactive arthritis. Transgenic mice for the human HLAB27 
and human B2 microglobulin genes, develop arthritis, gut inflammation, 
epididymitis, and skin lesions which strongly resembles spondyloarthropathy 
of humans. However a high copy of B27 gene is needed to bring in those 
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symptoms seen in human Spondyloarthropathy. Apart from the above theory, 
HLA B27 invokes an inflammatory response by the following process also. 
Heavy chains of HLA-B27 have an  unpaired cysteine at position 67 in 
the B pocket of the peptide binding groove which  leads to the formation of 
heterodimers and homodimers, which are recognised by NK cells and T cells. 
This unusual dimer stimulates CD4
+
 T cell when bound by peptides. 
Transgenic mice develop arthritis only when B2 microglobulin is lacking 
since its presence inhibits HLA B27 expression.  
HeLa cells transfected with HLA-B27 respond to in vitro bacterial 
invasion whereas controls don‟t. HLA B27 improves bacterial survival by 
alteration in protein folding which when done in endoplasmic reticulum  is 
slower. Protein misfolding is also common resulting in formation of 
proinflammatory cytokines and activation of Nuclear Factor kappa B.  
Presence of HLA B 27 reduces the ability of a cell to eliminate the 
infected macrophages normally. This results in prolonging the cellular 
survival of pathogens prolonging the inflammatory incitation and signals. 
Studies show that adhesion molecules of Yersinia and Salmonella use HLA-
B27 as a ligand to attach to cells of the synovial environment.  
Summarising   the role of  HLA B27 
1) Binds to an antigenic (self) peptide 
2) Unfolded Protein Response 
3) Homodimer formation resulting in recognition by NK cell receptors 
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4) Altered intracellular killing in certain infections, suggesting that 
infection or immune response may act as a trigger.  
HLA B27 may influence the human microbiome. Change in 
microbiome predisposes to AS. Bacteria implicated in causing reactive 
arthritis are not often cultured nor demonstrated in synovial samples. 
However bacterial products like lipopolysacchrides are found in the affected 
joints. They are highly antigenic and trigger an inflammatory reaction 
resulting in arthritis. Lipopolysacchrides can activate tumour necrosis factor 
α, which has been known to be the major cytokine in reactive arthritis. 
Genetic polymorphisms of TNF α can itself trigger a spondyloarthritis.585,9 
TNF α production is controlled by Nuclear Factor kappa B and Mitogen 
Activated Protein Kinases. HLA B27 affected cell lines reduces the inhibition 
of NFkappa B and thereby increases the TNF α production.60  
NON-ANTIGEN-PRESENTING EFFECTS OF HLAB27 
Apart from the above described antigen presenting models of HLA B 
27 affected cell lines there is evidence suggesting a role of non antigenic 
presenting effects also, in that it induces altered inflammatory response.  It 
was shown in   an experimental mouse model that mice expressing HLA B27 
positivity lacking B2 microglobulins developed arthritis. Therefore it was said 
that rather than presence of HLA B27 HC dimers, absence of β2 
microglobulin results in developing arthritic symptoms after an initial trigger.  
ROLE OF AUTO ANTIGENS 
Once reactive arthritis becomes chronic and persistent the pathogenesis 
shifts from an infectious process to an autoimmune process. As like in 
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ankylosing spondylitis, whether autoantigens like collagen II or proteoglycans 
play a role has to be further explored. 
HLA B27 AND SALMONELLA INFECTIONS 
Patients with reactive arthritis due to a preceding Salmonella infection 
have elevated Immunoglobulin IgM, IgG and IgA concentrations when 
compared to people without joint symptoms after the infection.
61,62
 These 
immunoglobulins last longer and are often persistent. In patients with 
Yersinia infection IgA levels are persistently elevated suggesting that the 
antigenic stimulation is from an enteric source. Antigenic products  of the 
infective organism stay in white blood cells for many years after an initial 
infection
63
. This phenomenon is often observed in patients with HLA B 27 
positivity. 
The bacteria involved in reactive arthritis are capable of surviving 
intracellularly. HLA B27 has been studied to have a role in modulation of 
intracellular survival of pathogens. Monocytes and macrophages form the first 
line of defence against Salmonella, However HLA B27 affected monocytic 
cells and fibroblast cells showed reduced elimination of Salmonella after the 
initial infection. But the intestinal survival of Salmonella is not affected by 
HLA B27 positivity. Cells expressing HLA B27 will allow the intracellular 
replication of Salmonella.
64 
HLA B27 does not influence the pathogenesis of Chlamydial ReA. It 
neither influences the invasion nor replication of Chlamydia trachomatis 
infection in cell line. 
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CYTOKINES IN REACTIVE ARTHRITIS 
Analysis of cytokine profile in ReA states that the TH1 cytokines such 
as TNF α and IFN-γ are low in patients with acute ReA. Normally TH1 
cytokines mediate a protective against intracellular pathogens. Elevated IL12 
level leads to the suppression of TNFα and IFNγ. This imbalance resulting in 
elevated TH 2 cytokines leads to decreased bacterial clearance and disease 
persistence. However enhanced production of TNF α and IFN -γ is observed in 
chonic ReA.  
IL 17 IN REACTIVE ARTHRITIS 
Th17, a third cell line in the subset of helper T cells plays an important 
role in many autoimmune and inflammatory diseases, of which most studies are 
in the group of spondyloarthritis. It also plays a pathogenetic role in primary 
Sjogren‟s syndrome, Multiple sclerosis and Rheumatoid arthritis.65,66  In mouse 
cell lines Th17 cells depend on transforming growth factor β1 and Interleukin 6 
for their differentiation. In   humans   it depends on Interleukin 1 and interleukin 
6.
67
 An expansion of Th17 cells need IL 23 which is common both to mouse and 
human cell lines. IL-23, a heterodimeric cytokine is made of a unique p19 
subunit which is linked to a common p40 chain.
67
 Importantly p40 is associated 
with a  p35 chain and forms IL-12, a cytokine which plays a role in Th1 
differentiaition.
68
  Yersinia infected mice with p40
5
developed  acute reactive 
arthritis whereas ones with TNFRp55
-
 developed chronic arthritis.
69
 A study 
from India has demonstrated an increased level of various cytokines(1L 17,IL 6, 
IFN γand TGF β) in the plasma and in synovial fluids of patients with reactive 
arthritis.
70
 Recent data suggest that IL 17 plays an important role in the spectrum 
of spondyloarthritis.
71
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CLINICAL FEATURES 
Reactive arthritis occur in the second to fourth decades of life. The 
male to female ratio following urogenital infection is 9:1 and 1:1 following 
enteric infection
72,73
. It has articular, enthesopathic and extraarticular features. 
It not only affects the joints but also has systemic features. Gastrointestinal  
symptoms appear before 1 month in postdysenteric ReA and urogenital 
symptoms appear 1-6 weeks before articular manifestations. It has both acute 
symptoms (6 months) and chronic symptoms (>6months). 
ARTICULAR  MANIFESTATION 
It includes both axial and peripheral joints. 
Peripheral joints are the most commonly affected joints. It presents as 
an asymmetric non erosive oligoarthritis. Sensitivity and specificity of 
oligoarthritis distribution is 44% and 95%.Knee, ankle and hip joints are 
commonly involved. Elbows, shoulders and wrist joints can also be involved. 
Polyarticular forms can also occur which include interphalangeal joints of 
toes, metatarsophalangeal joints and subtalar joints.
74,75
 Axial joints 
frequently affected are the sacroiliac joints and lumbar spine. Thoracic and 
cervical spine are affected in chronic reactive arthritis. Sternoclavicular and 
costosternal  joints can also be affected. Frequency of inflammatory back pain 
due to sacroilitis is 14-49% (with sensitivity and specificity of 71% and 77% 
respectively), spondylitis 12-26% and ligamentous insertion inflammation of 
ischial tuberosity in 15-30%.Chronic recurrent arthritis occurs in 15-30% of 
cases and occurs most commonly in Chlamydial infection.Dactylitis occur in 
16% of cases of ReA and is very distinct with a specificity of 99%.
76,77 
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ENTHESOPATHIC SYNDROME 
Enthesitis is very specific for reactive arthritis. Commonly involved 
sites are the plantar fascia and Achilles tendon. Frequency of enthesitis is 
about 30%. 
MUCOCUTANEOUS SYNDROME 
Keratoderma blenorrhagicum or palmoplantar pustulosis is the typical 
skin lesion of reactive arthritis which commonly occurs over the palms and 
soles and the frequency is 5-30%.
78
Circinate balanitis which occurs over the 
glans penis is seen in 4-20% of cases. Oral ulcers over the gingivae, hard 
palate, cheeks and tongue occur in 5-10% of patients.6-12% of patients may 
have nail dystrophy. Yersinia Induced reactive arthritis can have erythema 
nodosum in 15% of cases.
79
 Erythema Nodosum is not associated with the 
presence of HLA-B27. 
OCULAR MANIFESTATIONS 
Conjunctivitis occurs in 30% of patients with Shigella, Salmonella and 
Campylobacter infections, 35% of Chlamydial infections and 10% of 
Yersinial infections. It can be unilateral or bilateral with a mucopurulent 
discharge. Its course is often transient and mild
80
. Acute anterior uveitis 
occurs   in 5% of patients. Among these 50% can have HLA-B27 positivity.It 
is usually acute, painful and unilateral.
81,82
. Keratitis, scleritis, corneal 
ulceration are other less common manifestations
83
. Glaucoma, posterior 
synechia, cystoid macular edema and cataract can occur due to chronic 
inflammation
84
. 
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CARDIAC MANIFESTATIONS 
Conduction disturbances occur in 5 -14% of patients with acute 
ReA.
85
.It is related to HLA-B27 presence. Aortic valvular incompetence 
occurs in the chronic phase.
86 
Renal abnormalities include Haematuria, Pyuria and Proteinuria.  
Genitourinary symptoms which occur commonly with Chlamydial 
infections include Prostatitis which occur in 80% of patients, cervic itis, 
haemorrhagic cystitis and urethritis.  
LABORATORY INVESTIGATIONS 
 Diagnosis of Reactive arthritis is made mainly on the clinical 
symptoms since there is no definite diagnostic criteria. Reactive arthritis 
follows two different disease courses. The first one is with an acute course 
followed by resolution of symptoms gradually. During this phase patients can 
have elevated ESR and CRP. Other Inflammatory markers such as 
leukocytosis and thrombocytosis may also be found. Some patients may have 
a chronic course. They often have normal acute phase reactants. Aseptic 
pyuria may be seen in urinalysis. Rheumatoid factor and antinuclear 
antibodies are negative.
87 
SEROLOGY FOR CHLAMYDIA INFECTIONS  
Chlamydia induced reactive arthritis is based on the evidence of 
preceding urethral or cervical infections
88
.30-50% of cases of posturethritic 
ReA,69% of patients who had prior urogenital inflammation  have evidence of 
chlamydial infections
89
.Microimmunofluoresence is the gold standard 
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serological test. Here the elementary bodies are fixed to glass slides to which 
specific immunoglobins are added,to detect IgG and IgA antibodies . EB 
bodies should be treated to remove lipopolysaccharides.  It  is costly and not 
suitable for testing large number of samples, but may be useful to 
discriminate between different serovars. Chlamydial culture is the gold 
standard test for diagnosis.
90
Its sensitivity is 70-80%. Antigen-detection tests 
such as direct fluorescent-antibody assay, enzyme Immunoassay, 
Immunoblotting, and Nonamplified nucleic acid hybridization are used in the 
diagnosis of chlamydial infection.Newer technologies such as Polymerase 
Chain Reaction, Ligase chain reaction, Hybrid capture system, Transcription-
mediated amplification of RNA, Strand displacement assay may also help in 
diagnosis. They are of low expense, sensitive and timely available over 
culture
91,92
. Nucleic Acid amplification tests have a sensitivity and specificity 
of 82-100%.Immunofluoresence and Direct fluorescent antibody assay has 
sensitivity of 70-80% and specificity of 96-100%.Enzyme immunoassay based 
on peptides detecting IgG and IgA in serum samples of reactive arthritis have 
a sensitivity and specificity of 74% and 84% respectively.
93
Antibodies should 
combine tests for IgG, IgM and IgA antibodies. Antigens commonly used in 
the detection are   MOMP   and  LPS.ELISA using these synthetic peptides 
are also useful with a sensitivity and specificity of 78% and 73% respectively. 
Determination of synovial fluid antiMOMP IgG and IgA are more specific 
with specificity around 80% and 90% respectively.
94 
Differentiation between 
Chlamydia species is essential because of high prevalence of cross reactivity 
with Chlamydia pneumonia species. 
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DIAGNOSIS OF ENTERIC REACTIVE ARTHRITIS 
For diagnosing enteric related reactive arthritis with preceding 
enteritis, stool culture appears to be useful. Yersinia and Salmonella are 
detected in stool culture only in 9% of patients who have preceding diarrhoea 
in 4 weeks. 
95 
SEROLOGY FOR YESINIA INFECTION  
.In Yersinia induced reactive arthritis stool cultures are rarely positive, 
since the culture requires a special technique. Regarding the serological 
diagnosis both ELISA and EIA are used. Indirect Haemagglutination test was 
the first test used to detect Yersinial infections. Yersinia adhesion protein 
(YAD), YIL, and invasins are the adhesion molecules involved in the 
pathogenesis. Antibodies against these antigens increase in acute infections. 
YAD of enterocolitica and pseudotuberculosis are implicated in ReA. Most 
data are with EIA using either LPS or OMP as the antigens.
96
 IgG and IgA 
isotopes are detected in patients with chonic reactive arthritis and IgM, IgG 
and IgA in patients with acute ReA. IgA antibodies persist for 14 to 16 
months in patients with arthritis and in those without arthritis for about 5 
months. IgG antibodies also persist longer but not as IgA
97
. 
SEROLOGY FOR SALMONELLA INFECTIONS 
Salmonella antibodies can be demonstrated by both agglutination and 
ELISA. Initially used was the agglutination test where the sera of  typhoid 
patients agglutinated with formalin fixed host bacterium. O antigens and 
flagella were used. These tests underwent modification and currently sera 
from typhoid patients are mixed with killed salmonella typhi. If antibodies are 
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present agglutination occurs. Anti IgO antibodies appear first, later by 
antiIgH in chronic phase. AntiIgV antibodies detect carrier status. Widal 
agglutination detects IgM antibodies and its sensitivity is low. ELISA is 
specific detecting different Immunoglobin classes and is preferable to 
agglutination. Sensitivity of  ELISA is approximately 92% for detecting 
salmonella antibodies in both acute and late infections. These antibodies 
persist for 9- 14 months in patients with ReA than with enterocolitis which is 
about 4 months. In Salmonellosis response is seen in all classes of 
Immunoglobins compared to Yersiniae which has predominantly IgA class.  
Shigella flexerni, Shigellla sonnei, Shigella dysentriae are the species 
identified in the etiology of reactive arthritis. It is diagnosed on the basis of 
stool culture. No specific serological test is available for diagnosis of 
Shigella. More advanced luminex technologies are used in the diagnosis of 
invasive plasmid antigens and the lipopolysaccharides of Shigella species
98
. 
Campylobacter jejuni infections can be detected by 
Immunofluorescence, Complement fixation and Agglutination techniques. 
Enzyme immunoassays  used to detect antibodies to antigens such as LPS 
have sensitivity of  71%,60%,80% to IgG, IgA and IgM  antibodies and 
specificity of 90%.Recently new antigens such as flagellin, Major Outer 
Membrane protein and periplasmic associated  membrane protein can be 
detected by ELISA. 
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POLYMERASE CHAIN REACTION 
Polymerase chain reaction is used in the detection of bacterial species 
DNA .However synovial membrane biopsy is more useful than PCR in the 
detection of bacterial DNA. Chlamydia is found to be positive in 65% of 
patients with reactive arthritis by PCR. Chlamydial DNA is also found to be 
positive in 21% of patients with RA, 35% of patients with OA and healthy 
subjects.
99
These results showing the presence of chlamydial DNA in patients 
other than ReA limits the usefulness of detecting organisms by PCR.There is 
no role of PCR in detecting Salmonella or Yersinia.  
TREATMENT 
There is no specific treatment for ReA. Management of ReA aims at 
the control of pain and prevention of joint destruction and preservation of 
joint function. 
PHARMACOLOGIAL THERAPY 
NSAIDS: NSAIDS both COX1 and COX2 Inhibitors play a key role in the 
management of ReA. They are helpful for articular symptoms. They are not 
useful in extraarticular symptoms.
100-102
NSAIDS may prevent radiological 
progression in other types of SPA but its role in chronic ReA arthritis is not 
known. No one NSAID is superior over another.  NSAIDS are believed to 
potentiate the antiproteolytic potential of antibiotics and  the facilitate entry 
of antibiotics to the site of inflammation. 
STEROIDS 
They are helpful for peripheral arthritis and not useful in axial arthritis. 
Intraarticular steroids may be helpful in monoarthritis. Topical steroids are 
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helpful in extra-articular manifestations such as iritis, balanitis and 
Keratoderma blenorrhagicum. Systemic steroids are indicated in severe 
polyathritis and atrio-ventriular conduction disturbances
103
. 
ANTIBIOTICS 
Since reactive arthritis is triggered by bacteria the role of antibiotics in 
the treatment of ReA has been suggested. Eradication of pathogen may 
prevent the subsequent arthritis
104
 and shorten its course
105
.Antibiotics usage 
may be helpful in ReA due to urogenital infection than gastrointestinal 
infections
106
. 
ANTIBIOTICS IN UROGENITAL ARTHRITIS 
Studies have shown that prompt treatment of urogenital infections 
reduces relapses of reactive arthritis. A study performed in Greenland which 
has a high frequency of HLA B27 and ReA showed that the incidence of 
postvenereal reactive arthritis significantly reduced from 37% in untreated 
patients to 10% after treatment with Erythromycin or Tetracycline
107
.In 
Chlamydia induced ReA, treatment with Lymecycline for 3 months reduced 
the duration of arthritis in the treatment group to 15 weeks compared to 
placebo group which was around 39 weeks
108
. But long term treatment did not 
change the course 
109,110
 .Clinical parameters also improved with the treatment 
of minocycline
111
. Sieper et al showed that Ciprofloxacin was superior to 
placebo in Chlamydia induced reactive arthritis. Chlamydia induced urethritis 
can be treated with either Doxycyline 100mg twice a day or Azithromycin 1 
gm orally as a single dose or Ofloxacin 300mg twice daily. Sexual partner of 
the patient should also be treated .Acute ReA due to Chlamydia can be treated 
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with Tetracycline or Ciprofloxacin for 4 to 12 weeks. Studies have also shown 
beneficial effect of combination therapy with Azithromycin and 
Rifampicin
112
.A study in 2004 showed that combination therapy with 
Rifampin and Doxycycline showed significant improvement than with single 
therapy of Doxycycline in Chlamydia induced reactive arthritis
113
. 
ANTIBIOTICS IN ENTEROARTHRITIS 
Several reports have shown that antibiotics have no effect in the 
development of ReA due to gastrointestinal infections.
114
 Antibiotic trials in 
Salmonella enteric serovars using Ciprofloxacin, Ofloxacin, Doxycycline and 
Cotrimoxazole  showed no benefit
115,116
. In a non-blinded prospective study 
of patients with enteroarthritis  secondary to agents such as Salmonella, 
Yersinia, Enterocolitica or Campylobacter conducted by Fryden et al showed 
that treatment with or without antibiotics showed no difference in dura tion of 
arthritis, involvement of the number of joints and the degree of 
inflammation.
117
  Treatment with antibiotics  either with Ciprofloxacin or 
Tetracycline for 3 months in patients with reactive arthritis secondary to 
enterobacterial infection  did not show beneficial effects over placebo in long 
term controlled studies.
118-121
in the early stages of ReA. However a study 
shown by Yli-kerttula et al showed that in patients treated with ReA in the 
acute phase with Ciprofloxacin for 3 months when followed after 4 to 7 years 
had better outcome than the placebo group
122
. 
SECOND LINE THERAPIES 
As discussed above NSAIDS have shown benefit only in few patients, 
hence the usage of DMARD therapy has been discussed.
123 
 36 
SULFASALAZINE 
Sulfasalazine is the best studied DMARD.A prospective placebo 
controlled trial of 134 patients demonstrated improvement in 62% of 
participants compared with 47% of placebo controlled 
participants
124
.Sulfasalazine exerts beneficial effect by  reducing the mucosal 
permeability to antigens.
125
 It also has antibacterial action
126
.However there 
was no significant improvement in  clinical parameters such as tender joint or 
swollen joint count. As 67% of patients with reactive arthritis have underlying 
inflammatory bowel disease, this might be   a therapeutic option in patients 
with postenteric variety
127
. 
METHOTREXATE 
Though Methotrexate has been used widely there are no controlled 
studies to show its beneficial effects .
128,129 
AZATHIOPRINE 
Azathioprine has been found to be beneficial in peripheral arthritis at a 
dose of 1to 2 mg/kg in few placebo controlled studies 
130,131
. 
Other DMARDS which have been tried are Cyclosporine, Leflunomide, 
Cyclophosphamide, 6 Mercaptopurine and Levamisole however there are no 
controlled studies
132
. 
TUMOR NECROSIS FACTOR ANTAGONIST 
TNF-α antagonists have been shown to have great success in the 
treatment of spondyloarthropathy. Its role in   reactive arthritis has  many 
theoretical concerns. Reactive arthritis is TH2 mediated disease and TNFα is 
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found to be low 
133,134
. ReA is most commonly trigerred by Chlamydia
135,165
 
and persistent Ct and Cpn levels are inversely associated with TNF 
levels
137,138
..But inversely patient with reactive arthritis are found to have 
high TNF levels and hence TNF α antagonist are useful.139.There  are only 
case reports and open label studies which  have analysed the role of TNF 
antagonists but no controlled studies are available
140.141
.However treatment of 
reactive arthritis induced by Chlamydia had led to the increase in bacterial 
load when compared to pretreatment level. This has been demonstrated by 
synovial biopsy in an open label trial and hence it may not be useful in 
chronic Chlamydia induced arthritis. But it may be useful in postenteric 
variant of reactive arthritis since there is no persistence of viable 
microorganism. However the role of TNF antagonist usage in reactive arthritis 
is unanswered. 
PROGNOSTIC FACTORS 
Prognosis of ReA is affected by the nature of triggering infection, gender of 
the patient and presence of HLAB27 and the occurrence of recurrent 
symptoms.
142
 Persistence of inflammatory foci in the gut and recurrent 
urogenital infection lead to the progression of chronic reactive arthritis to 
SPA.
143
.HLAB27 is associated with severe disease, extra-articular 
manifestations and higher frequency of sacroilitis.
144
.Male sex and family 
history of SPA are adverse factors.  
COURSE 
Reactive arthritis follows various courses .It can be self limiting and short, 
recurrent or continuous or unremitting .The duration of acute arthritis i s 6 
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months. Arthritis persisting after 6 months is said to have a chronic 
course.
145
.Duration of arthritis is about 3-5 months on an average in Finnish 
study. Enthesitis, balanitis, and skin lesions tend to persist even after the 
inflammation in joints have subsided .75% of patients go in for complete 
remission at the end of 2
nd
 year when all symptoms are taken into account.15-
30% of patients may have a chronic course
146
. 
PROGNOSIS 
Prognosis of reactive arthritis is good and the disease duration 
generally varies from days to weeks. About 15-30% of patients develop 
chronic reactive arthritis either peripheral or axial arthritis. Reactive arthritis 
triggered by Shigella , Salmonella and Yersinia infections are best known. 
Recurrent attacks are frequent in these patients
147,148
.16% patients developed 
reactive arthritis after a mean of 11years in a Finnish study
138
.Similiarly in a 
study with Yersinia induced ReA about one third of the patients developed 
sacroilitis
149
.In a 20 year follow up study in patients with Shigella induced 
arthritis 32/100 had Ankylosing spondylitis
150
.HLAB27 patients developed 
recurrent or chronic symptoms. Prognosis in HLAB27 positive patients is less 
favourable
151
. 
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MATERIALS AND METHODS 
PLACE OF STUDY 
This cross sectional study was conducted in the Department of 
Rheumatology, Madras Medical college and Rajiv Gandhi government 
General Hospital, Chennai. 
STUDY PERIOD AND DESIGN 
This study was done for a period of one year from January 2013 to 
January 2014. 
ETHICAL CONSIDERATION 
Approval was obtained from the institutional ethical committee before 
the commencement of the study. Informed consent was obtained from the 
study population. All patients satisfying the inclusion criteria were 
documented. Patients were interviewed by structured questionnaire. 
STUDY POPULATION 
Sample size 
After analyzing 100 patients who attended the Rheumatology OPD  
with predominant lower limb arthritis,46 patients who satisfied the diagnostic 
criteria for Reactive arthritis were chosen for the study.  
Inclusion criteria 
 Patients satisfying the diagnostic criteria for Reactive arthritis  
. 
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Exclusion criteria 
 JIA  
 Septic arthritis 
 Inflammatory polyarthritis of known connective tissue disorders such 
as Ankylosing spondylitis, Rheumatoid arthritis and Psoriatic arthritis. 
STUDY  
After thorough clinical examination all these patients underwent 
routine laboratory investigations such as Haemogram,  Liver function tests and  
Renal function tests. Ultrasound was done in these patients to confirm the 
arthritis and enthesitis.CT pelvis was done at the  onset and after 1 year to  
look for the radiological evidence of  sacroil itis. 
All patients underwent ECHO and Opthalmological examination. 
Dermatogical consultation was obtained whenever necessary.  
 Urine culture was done in patients with dysuric symptoms. 
 URINE CULTURE 
 Urine culture is done by inoculating a loopful of urine on blood agar 
and Macconkey agar. The  inoculated plates are incubated aerobically at 35-
37ºc overnight. 
Colonies that are normally found on blood agar and MacConkey agar are 
a. Escherichia coli 
b. Proteus species 
c. Pseudomonas aeruginosa 
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d. Klebsiella strains 
e. Staphylococcus aureus 
f. Enterococci 
Additionally to detect S.typhi 7-10ml of urine is centrifuged   in  a test tube at 
high speed for 5-10minutes , the supernatant fluid  is removed and the sediment 
transfered to selenite enrichment broth at 35-37ºC, then subcultured on the plate 
and incubated at  35-37ºC for 24 hours. 
After  24 hours look for the colonies. Most urinary infections produce growth of 
single type of organism. Count the approximate no of colonies. Estimate the number 
of bacteria (colony forming unit /ml of urine) 
A bacterial count of 100000/ml or more indicates a urinary infection. 
Urine PCR was used to detect Chlamydia species in few patients due to cost 
constraints. 
 STOOL CULTURE 
       Stool culture was done in patients with history of diarrhoea. In our set up we have 
culture medium to identify only Salmonella and Shigella. Campylobacter and 
Yersinia species could not be identified. 
A loopful of the emulsified faeces or fluid specimen transported in special medium 
such as Cary-blair medium, is inoculated on XLD agar and several loopful into 
selenite F enrichment broth. The XLD agar pate is incubated aerobically at 35-37ºC 
overnight. 
XLD agar  
         This selective medium is recommended for the isolation of Salmonella and 
Shigella from the faecal specimens. It contains the indicator phenol red which is red at 
alkaline PH and yellow at an acid PH. 
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SELENITE F BROTH 
This is an enrichment and selective broth for salmonella. It inhibits the 
growth of colifoms. 
After overnight incubation in XLD aga,Shigella form red colonies 
because they do not ferment xylose, lactose or sucrose. 
Salmonella form red colonies with black centre except S.Typhimurium.  
Escherichia coli, Enterobacter species produce yellow colonies.  
After identification of suspected Salmonella and Shigella species we 
have to perform lysine decarboxylase test and Triple  sugar  iron test  
Shigella –LDC negative 
Salmonella –LDC positive except S.Paratyphi. 
Then confirm with serological identification by slide agglutination 
technique by adding appropriate antiserum. 
Patients also underwent serological test for identification of Brucella  
(agglutination test) and salmonella typhi and Paratyphi. (widal agglutination 
test). 
CRP METHODOLOGY 
This test is based on the immunological reaction between CRP as an 
antigen and latex particles coated with monospecific anti-human CRP. It is a 
qualitative slide test. A  drop of test serum is placed  within the circle area on 
the special slide provided and a drop of the latex CRP reagent  is added. It 
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then mixed well and rocked gently in a to and fro motion . After 2 minutes 
agglutination is looked for. 
HLA B27 METHODOLOGY 
HLA B27 was done for  all the patients. In our lab the methodology used is 
complement dependent microlymphocytotoxicity assay. 
PRINCIPAL OF THE ASSAY 
The antibodies to HLA antigens used in this serological assay are known as 
allo-antisera, which are obtained from humans who had been sensitized to 
HLA molecules ,through previous pregnancy or previous transplantation or 
multiple transfusions of blood. Monoclonal antibodies produced through 
hybridoma techniques are also used. The cells used for the test are the 
peripheral blood mononuclear cells. Hence  when specific antisera are added 
to lymphocytes, antigen-antibody reaction take place. Subsequently when 
complement is added, complement will be utilized wherever antigen antibody 
reaction has taken place, resulting in complement mediated death of the cells 
bearing specific antigen. 
SAMPLE 
Heparinised blood is collected .Approximately 10 ml o blood sample is 
collected in 100microliter of heparin. (10,000units/ml) 
The blood and heparin are mixed thoroughly and gently.  
The testing should be done on the same day of collection. 
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REQUIREMENTS 
Terasaki plates (60 or 72 welled plate) 
Ficoll–hypaque (lymphocyte separation medium) .Graduated 10 ml 
centrifuge tubes. 
Pasteur pipettes,Phosphate buffered saline(PBS),Alloantisera of 
different specificity.Rabbit complement ,Eosin yellow 4% solution. 
Light liquid paraffin,Hamilton syringes 
Repeating dispenser with 50 divisions 
PROCEDURE 
STEP-1: Separation of peripheral blood mononuclear cells by 
differential centrifugation. 
The heparinised blood is diluted  1:1 with PBS.2ml of lymphocyte 
separation medium is taken in a centrifuge tube and about 8 ml of diluted 
blood is layered over it by adding the blood along the sides of the tube.  
The tube is then centrifuged for 30 minutes at 2000rpm. 
At the end of centrifugation, the RBCS get settled at the bottom of 
tube, while peripheral blood mononuclear cells are seen as a white band at the 
interface of lymphocyte separation medium and plasma.  
The cells are carefully harvested with help of pasteur pipettes and 
transferred to test tubes. 
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The cells are then washed 2-3 times in PBS by centrifuging at 1000rpm 
to get rid of platelets. 
The total number  of cells are adjusted to 2 million cells per ml of cell 
suspension by counting the cells in the Neubaur chamber.  
FIGURE-1 TERASAKI PLATE 
 
PLATING 
The Terasaki plates are coated with 1µl of different HLA  
allo-antisera. 1µl of cell suspension is added to antisera in the wells of 
Terasaki plates.The plate is incubated for 30 minutes at room temperature.  
One plate is utilized for each patient. 5µl of fresh complement is then added 
to all wells .The plate is incubated for 1 hour at room temperature.8µl of 
eosin yellow is added to all the wells and the reading is taken under inverted 
phase contrast microscope. 
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READING AND INTERPRETATION 
The  percentage of dead cells (cells which have taken up the dye and 
appear bigger, flatter and darker) are counted in each well.  
In the well coated  with positive control ,100% dead cells should be 
present. This assures the potency of complement 
In negative control well no dead cells should appear. This assures  non-
toxicity of reagents and smooth handling of cells.  
The percentage of dead cells found in the HLA B27 well are 
interpretated as follows 
100% dead cells –strong positive 
More than  50% dead cells –positive 
20-50% dead cells –weak positive 
Less than 20% dead cells –negative.  
FIGURE-2  HLA B27 TYPING  
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IL 17 A METHODOLOGY 
IL17A assay is done on these patients by ELISA 
STEP 1- Addition  
Preparation of Standard  
Standard vials must be reconstituted with volume of standard diluent. 
This gives a stock solution of 100pg/ml of IL17A. Serial dilutions of the 
standard are made directly in the assay plate to provide the concentration 
range from 100 to 3.125pg/ml.A fresh standard curve should be produced for 
each new assay. 
Immediately after reconstitution  add 200 µl of reconstituted standard 
to wells A1 to A2 which provide the highest concentration standard at 
100pg/ml. 
Add 100µl of appropriate standard diluent to the remaining wells B 1 to 
B2 .Continue this 1:1 dilution using 100µl from wells B1 and B2 through to 
wells F1 to F2 providing a serial diluted standard curve from 100pg/ml to 
3.125pg/ml.Discard 100µl from the final well of the standard curve.  
Step-2 Addition  
Add 100µl of each, sample and zero in duplicate to appropriate number of wells. 
Step-3: Incubation 
Incubate at room temperature for 2 hours.  
Step- 4: Incubation  
Wash three times with the wash buffer.  
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Step-5: Addition 
Add 50µl of diluted biotinylated anti-IL17A to all wells. 
Step-6: Addition  
Incubate at room temperature for 1hour. 
Step-7: Wash 
Repeat step 4 
STEP-8: ADDITION 
Add 100µl of streptavidine –HRP solution into all wells. 
Step-9: Incubation 
Incubate at room temperature for 30 minutes.  
Step- 10: Wash 
Repeat wash step 4 
Step-11: Addition  
Add 100µl of ready to use TMB substrate solution into all wells.  
Step-12: Incubation 
Incubate in the dark for 5-15 minutes at room temperature .Avoid 
direct exposure to sunlight. 
Step-13: Addition  
Add 100µl off H2SO4 stop reagent into all wells.Read the absorbance 
value of each well on spectrophotometer using 450 as primary wavelength and 
optionally 620nm as reference wavelength. Value above 3 is taken as positive. 
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Figure-3: IL 17A ELISA PLATES 
 
CALCULATION OF DAREA(Development of a disease activity 
index for the assesement of Reactive arthitis) 
DAREA is computed by adding the Swollen joint count + Tender joint 
count + Global Health assessment + Patient‟s pain assessment + 
CRP(mg/dl).Patient‟s global assessment is taken on a 3 point scale 0=good, 
1=fair, 2=poor.Pain assessment by 3 point visual analog scale 0=none, 
1=moderate, 2=severe  
Statistical Methods:Descriptive statistical analysis has been carried out in the present 
study. Results on continuous measurements are presented on Mean  SD and results 
on categorical measurements are presented in percentage. (%). Chi-square test has 
been used to find the significance of study parameters on categorical scale between 
two groups. Student „t‟ test has been used to determine the significance between two 
group means. All analyses were two tailed and p <0.05 was considered significant. 
SPSS version 16.0 was used for data analysis.    
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RESULTS 
 Figure -4 Total no of Patients 
27
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NO OF MALES-27
NO OF FEMALES-19
 
Total no of patients studied were 46. Among them 58.7% were males 
and 41.3% were females. 
Table -2: Sex  and  Outcome(SPA) 
Sex  
Outcome 
Total 
SPA+      SPA- 
Male 
Count 6 21 27 
% within sex 22.2% 77.8% 100.0% 
Female 
Count 5 14 19 
% within sex 26.3% 73.7% 100.0% 
Total 
Count 11 35 46 
% within sex 23.9% 76.1% 100.0% 
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Chi-Square Tests 
 Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
(P Value) 
Exact Sig. (1-
sided) 
Pearson Chi-Square .103a 1 .749   
Continuity Correction .000 1 1.000   
Likelihood Ratio .102 1 .749   
Fisher's Exact Test    1.000 .508 
Linear-by-Linear 
Association 
.100 1 .751 
  
No of Valid Cases 46     
Sex has no significant correlation with the outcome. P Value 1.0 
Figure-5:  Mean Age and Duration 
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FEMALE-MEAN AGE AND DURATION
  
Total mean age of the patients is 29.91 years and the mean  duration is 
4.07 weeks. Mean age among  the males is 29.67years and their mean duration 
is 3.70 weeks. Mean age among the females is 30.26years and  their mean 
duration is 4.58 weeks. 
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 Figure -6: No of Patients with Gastrointestinal and Genitourinary 
Symptoms 
4
16 21
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DIARROHEA-21
NO OF PATIENTS WITH
DSYURIA-16
NO OF PATIENTS WITH WHITE
DISCHARGE-4
 
    Table -3: GI Symptoms 
Valid Frequency Percent Valid Percent Cumulative Percent 
Diarrhoea 21 45.7 45.7 45.7 
Nil 25 54.3 54.3 100.0 
Total 46 100.0 100.0  
Table -4: Genitourinary Symptoms 
Valid Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Dysuria/ White 
Discharge 
20 43.5 43.5 43.5 
Nil 26 56.5 56.5 100.0 
Total 46 100.0 100.0  
Among the 46 patients 45.5% had diarrhea and 43.5% of patients had 
genitourinary symptoms such as dysuria and white discharge  
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Table -5: GI Symptoms and Outcome(SPA) 
GI Symptoms  
outcome 
Total 
SPA+ SPA- 
Diarrhoea Count 9 12 21 
% within GI SYMPTOMS 42.9% 57.1% 100.0% 
Nil Count 2 23 25 
% within GI SYMPTOMS 8.0% 92.0% 100.0% 
Total Count 11 35 46 
% within GI SYMPTOMS 23.9% 76.1% 100.0% 
 
Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. (2-
sided)(PValue) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 7.621a 1 .006   
Continuity 
Correction 
5.826 1 .016 
  
Likelihood Ratio 7.986 1 .005   
Fisher's Exact Test    .013 .007 
Linear-by-Linear 
Association 
7.456 1 .006 
  
N of Valid Cases 46     
The proportion of SPA was significantly higher among the patients 
with Gastrointestinal symptoms.  p value is.0.013. 
Genitourinary symptoms had  no statistical significance with   the 
outcome (SPA).  
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Figure-7 No.of Patients with Serological Positivity 
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Total no of serology positive patients-37%. 
Salmonella positivity was found in 30% of the patients. 
Brucella positivity was found in 7% of the patients .  
   
Table -6: Salmonella  Positivity  and  SPA 
Salmonella  
outcome 
Total 
SPA+ SPA- 
Positive 
Count 8 6 14 
% within salmonella 57.1% 42.9% 100.0% 
Nil 
Count 3 29 32 
% within salmonella 9.4% 90.6% 100.0% 
Total 
Count 11 35 46 
% within salmonella 23.9% 76.1% 100.0% 
 55 
Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided)(p 
value) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 12.214a 1 .000   
Continuity 
Correction 
9.729 1 .002 
  
Likelihood Ratio 11.573 1 .001   
Fisher's Exact Test    .001 .001 
Linear-by-Linear 
Association 
11.948 1 .001 
  
N of Valid Cases 46     
The proportion of SPA is significantly higher among the patients with 
salmonella positivity, P Value 0.001 
Figure-8: Urine Culture positivity 
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Urine culture was positive in 20% of the patients. 
Chlamydia was identified by urine PCR in one person. 
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Figure-9 stool culture positivity 
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Stool culture was  positive in  4% of the patients.  
 
Figure -10 Inflammatory back pain   
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IBA was present in 50% of the patients 
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Table -7: IBA  and  SPA 
IBA  
Outcome 
Total 
SPA+     SPA- 
Present Count 11 12 23 
% within IBA 47.8% 52.2% 100.0% 
Absent Count 0 23 23 
% within IBA .0% 100.0% 100.0% 
Total Count 11 35 46 
% within IBA 23.9% 76.1% 100.0% 
 
Chi-Square Tests 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
P value 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 14.457a 1 .000   
Continuity 
Correction 
11.948 1 .001 
  
Likelihood Ratio 18.766 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear 
Association 
14.143 1 .000 
  
N of Valid Cases 46     
IBA had significant correlation with the outcome(SPA). P value0.000 
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Figure -11  HLAB27 and Spondyloarthropathy 
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HLAB27 was  negative  in 76.1% of patients . 
HLA B27 was positive in 23.9% of patients.  
HLA B27 positivity was seen in 81.8% of SPA patients. 
HLAB27 negativity was seen in 5.7% of SPA patients. 
Table -8: HLAB27 Positivity and SPA 
HLAB27   
outcome 
Total 
 SPA+ SPA- 
Positive Count 9 2 11 
% within HLAB27  81.8% 18.2% 100.0% 
Negative Count 2 33 35 
% within HLAB27  5.7% 94.3% 100.0% 
Total Count 11 35 46 
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Chi-Square Tests 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
(pvalue) 
 
 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 26.642a 1 .000   
Continuity 
Correction 
22.624 1 .000 
  
Likelihood Ratio 24.844 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear 
Association 
26.063 1 .000 
  
N of Valid Cases 46     
 The proportion  of SPA is significantly higher among the HLAB27  positive 
patients.P value is 0.000 
Figure-12-IL17APOSITIVITY                 
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Among the 46 patients, IL-17A  was positive in 47.8% and negative in  
52.2% of patients. 
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.FIGURE 13--IL17A AND SPA 
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TABLE-9: IL17 A Level and SPA 
IL17   
Outcome 
Total 
SPA+ SPA- 
Positive Count 8 14 22 
% within IL17  36.4% 63.6% 100.0% 
Negative Count 3 21 24 
% within IL17  12.5% 87.5% 100.0% 
Total Count 11 35 46 
% within IL17  23.9% 76.1% 100.0% 
. 
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Chi-Square Tests 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided)(P 
Value) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 3.593a 1 .058   
Continuity Correction 2.401 1 .121   
Likelihood Ratio 3.681 1 .055   
Fisher's Exact Test    .086 .060 
Linear-by-Linear 
Association 
3.514 1 .061 
  
N of Valid Cases 46     
36.4% of the  patients  with IL17Apositivity had SPA. It was not statistically 
significant. P Value is 0.86. 
Figure-14: DAREA SCORE -ONSET 
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Figure15- DAREA SCORE-6MONTHS  
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Figure -16 DAREA SCORE-1 YEAR 
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Table-10 
Chi-Square Tests 
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 7.621a 1 .006   
Continuity 
Correction 
5.826 1 .016 
  
Likelihood Ratio 7.986 1 .005   
Fisher's Exact Test    .013 .007 
Linear-by-Linear 
Association 
7.456 1 .006 
  
N of Valid Cases 46     
.The proportion  of  SPA is significantly higher among the patients with 
high DAREA score.P value is 0.007. 
 
FIGURE  17 DAREA SCORE AND IL17A ASSOCIATION 
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Table-11  DAREA AND IL-17A ASSOCIATION 
DAREA  
IL17A 
Total 
Positive Negative 
Mean score<14.5 Count 4 21 25 
% within DAREA 16.0% 84.0% 100.0% 
Mean score>=14.5 Count 18 3 21 
% within DAREA 85.7% 14.3% 100.0% 
Total Count 22 24 46 
% within DAREA 47.8% 52.2% 100.0% 
Mean DAREA Score  >14.5 was found in 85.7% of IL 17A positive  patients. 
Mean DAREA score <14.5 was found in 16% of IL17A positive patients 
Chi-Square Tests 
 Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided)(p 
value) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 22.229a 1 .000   
Continuity 
Correction 
19.523 1 .000 
  
Likelihood Ratio 24.474 1 .000   
Fisher's Exact Test    .000 .000 
Linear-by-Linear 
Association 
21.746 1 .000 
  
N of Valid Cases 46     
 IL 17A levels  correlated significantly with  high  disease activity 
score. P value is 0.000 
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FIGURE 18 CLINICAL OUTCOME OF REACTIVE ARTHRITIS 
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At the end of 1year 50 % of patients achieved remission.26% of the 
patients progressed to chronic ReA and 24% of the patients had SPA. 
FIGURE19- RADIOLOGICAL  OUTCOME  (SACROILITIS) 
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FIGURE-19- HLA B27 AND RADIOLOGICAL OUTCOME 
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Radiological positivity was found in 23.9% of the patients.  9 patients 
had association  with HLA B27. 
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DISCUSSION 
This is a cross sectional prospective study conducted in our institute to 
study the clinical features and outcome of reactive arthritis .When we analysed 
the history of Spondyloarthropathy patients attending our institute we found 
that many of them attribute an episode of infection when they first noticed 
their joint symptoms. Hence we have chosen this study about reactive arthritis 
and its outcome . 
We have chosen the diagnostic criteria proposed by the third 
international workshop for categorizing the patients with reactive arthritis,  
since we find it applicable in our set up where we do not have certain 
essential diagnostic tests proposed in the  latest preliminary criteria . More   
over the preliminary criteria has not been validated.  We have also analysed 
the association of reactive arthritis with HLA B27.  
Serum samples of these patients were collected and IL17A levels 
analysed. 
Among the 46 patients studied, 58.7% of the patients were males and 
41.3% of them were females. Mean duration from the onset of symptoms to 
the manifestation   of the disease was 4.07 weeks According to Towen et al  
after an episode of infection arthritic symptoms may appear upto 
4weeks
152
.Males were more affected than females in our study. The average 
age in our study was 29.91 years. According to Wright V et al the average age 
group is 20-40years
153
.Though males are more affected than females, outcome 
of the disease did not have statistical significance with sex.  In our study at the 
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end of 1yea ,11 patients had SPA,  out of which 6 were males and 5 were 
females.It did not have statistical significance. 
  The joints commonly affected in our study were the ankles and knees. 
Plantar fascia and Achilles tendon were the most commonly affected entheses. 
This is in concurrence with the study done by Carter et al.
38
 Dactylitis was 
seen in 6 patients.4 patients had conjunctivitis and one had  uveitis. Balanitis 
was seen in one patient. 
IBA was present in about 50% of the patients. It had statistical 
significance with the outcome. All the patients who had spondyloarthropathy 
at the end of the study were found to have IBA.(p<.000). Sigal et al studied  
the sensitivity and specificity of inflammatory back pain in ReA which was  
71% and 77% respectively.
170 
At the end of 6 months,28% of the patients had complete resolution of 
the symptoms as evident by the DAREA score of 0 and at the end of 1year 
54% of the patients showed complete resolution. Though 72% of  the patients 
showed persistent disease activity at end of 6months,  their score was low 
compared to the  score at the onset.At the end of 1year 23.9% of the patients 
progressed to spondyloarthropathy and 21.7 % of the patients had chronic 
arthritis as evidenced by DAREA score>1.According toMichet CJ et al about 
30-50% of the patients may progress to chronic ReA
171
.     
IL 17A levels were high in 22% of the patients.  Proportion of patients 
with IL17A positivity correlated well with disease activity.   
 69 
Analysing the symptoms associated with ReA in our study both 
gastrointestinal and genitourinary symptoms were associated with almost 
equal frequency. But gastrointestinal symptoms were 2.2% higher than 
genitourinary symptoms. 
The organism commonly associated with reactive arthritis in our study 
was Salmonella. Salmonella paratyphi is the common subspecies identified by 
serological method. 
 Many outbreak studies have been published since 2000 on the 
outbreak of salmonella species and the reactive arthritis associated with it.  In 
a study from USA by Dworkin et al   in 2001 on 217 patients with salmonella 
enteritidis, 29% patients of developed reactive arthritis
154
.But none of the 
patients were associated with HLAB27. 
In a study from Germany on 286 children with salmonella enteritidis 
by Rudwaleit et al in 2001 none of the patients developed reactive 
arthritis
155
.In a study from Denmark in 2002 by Locht et al on 94 patients 
with Salmonella enteritidis 19% of patients developed reactive arthritis.
156
 
In a study by Hannu et al from Finland in 2002 on 78 patients with 
Salmonella typhimurium 8% of patients had reactive arthritis
157
.2 persons had 
association with HLA B27.He also concluded that the  frequency of reactive 
arthritis after various enteric infections was around 10%.A Canadian based 
study in 2005 by Lee et al on 261 patients with Salmonella typhimurium  
showed that 14.6% of patients developed reactive arthritis.  HLA B27 was 
associated with 5/30 patients.
158
An Australian study in 2008 by Rohekar et al. 
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on 592 patients with Salmonella enteritidis revealed that 19.2% patients 
developed reactive arthritis.5/37 Patients had association with HLA B27
159
. 
 In our study out of 21 patients who presented with GI symptoms 
78.5% of patients developed reactive arthritis. The draw back in our study is, 
out of 46 patients only 2 patients had acute diarrhea. Other patients had 
history of diarrhea and presented to us with arthritis. Hence the stool culture 
did not give us a positive result.  
Though we focused mainly on the outcome,the  common organism 
identified in our study was Salmonella paratyphi.Serological positivity 
obtained in these patients was by Widal agglutination test. These patients had 
a higher O antigen titre. We were not able to conclude that it is the typhoidal 
species or the cross reaction with other enteritidis producing Salmonella 
species such as as S.typhimurium that produced the positivity.Organism   
isolation was the main drawback of our study.  
There are only few studies analysing the outcome of reactive arthritis.  
In our study about 57.1% of patients with Salmonella positivity had SPA.In a 
study by M Leirisalo-Repo et al on the long term prognosis of   Salmonella 
36% of patients developed chronic arthritis
160
.  In an American study by  
Thomson GT et al on the long the term sequelae of Salmonella arthritis,about 
half of the patients developed spondyloartropathy
161
 . 
In our study HLA B27 was present in 23.9% of patients and was 
present in 81.8% of the patients with spondyloarthropathy. It was statistically 
significant.(p=0.000). HLAB27 was found to be present in about 30-50% of 
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patients with reactive arthritis. Based on the epidemiological studies 
association with Salmonella, Campylobacter and Chlamydia induced ReA is 
50%
162
. In Shigella   induced ReA it is about 80%.
163
 
       In our study the association of Salmonella and HLA B27 was around 
63.63%.In 1998 Mattilal et al has revealed that the association of HLAB27  
with Salmonella Bovismorbificans was around 45%
165
.Studies from England 
and Scandinavian countries showed 97% prevalence of HLAB27 in patients 
with reactive arthritis after Salmonella infections.
166
 Leirisalo et al showed  
in his study that  2 out of 9 patients developed Spondyloarthropathy and they 
were associated HLA B27
167
. In a study by Seiper et al in 2002 the 
association of HLA B27 with enteric pathogens was about 50%.
168 
We have also analysed IL17A levels in these patients.To the best of 
our knowledge this is the first South Indian study where we have analysed 
IL17A levels in the serum of patients with reactive Arthritis.  IL 17A levels 
were elevated in 47.8% of the patients. Patients with elevated IL 17A levels 
had a persistent high disease activity score and had progressed to SPA and 
chronic reactive arthritis.  
DRAWBACKS OF OUR STUDY 
We were not able to carry out tests for identification of Chlamydia in 
all patients with dysuria. We were not able to carry out test for 
Campylobacter and Yersinia which are also commonly implicated in reactive 
arthritis ,due to non availability of the antiserum. 
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                               CONCLUSION 
 Knees and ankles were the commonly affected joints.  
 Plantar fascia and Achilles tendon were the commonly affected 
entheses. 
 Extraarticular manifestations were not commonly observed in our 
study. 
 IBA has significant association with the outcome.  
 Patients with high mean DAREA score at the onset progressed  to   
chronic reactive arthritis and Spondyloarthropathy.  
 Persistent disease activity was found in patients with elevated IL17A 
levels.  
 HLAB27 was found to be associated with 11/46 patients. Among the 
HLA B27patients,9patients had spondyloarthropathy. 
 11/46 patients had CT evidence of sacroilitis at   follow up. 
 Salmonella is the most common organism associated with reactive 
arthritis in our study. 
. 
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PROFORMA 
Name:    Age:   Sex:   Date: 
RCC No: 
H/o. Present Illness: 
Past History: 
Personal History: 
Treatment History:  
Family History: 
GENERAL EXAMINATION 
Pallor:   Icterus    Cyanosis 
Clubbing:   Lymphadenopathy  Pedal Edema 
Skin    Nails 
Hair 
Puse Rate    Blood Pressure 
SYSTEM EXAMINATION 
Cardiovascular System  Respiratory System 
Abdomen     Central Nervous System 
Musculoskeletal System Examination 
Dermatology 
Ophthalmology 
INVESTIGATION 
Haemogram 
Hb:    TC:    DC 
Platelet:   ESR: 
Immunological 
CRP   RF   ANA 
Biochemical 
Sugar:   Urea:    Creatinine: 
Radiography 
USG Abdomen & CT Pelvis 
Cultures 
Urine   Blood    Stool 
Swab 
Throat  Urethral   Cervical 
ECHO 
DAREA SCORE 
HIV 
URINE THROAT IBA
CULTURE SWAB
1 GOPAL 23 M 55174 2 MONTHS DIARRHOEA NIL SALMONELLA TYPHI NIL NIL NIL NIL BOTHKNEE,ANKLE
2 AKKEM 40 M 55178 1MONTH DIARRHOEA NIL SALMONELLATYPHI NIL NIL NIL NIL ANKLE ,KNEE,MIDTARSAL
3 ANBU 24 M 50912 1MONTH NIL NIL NIL NIL NIL NIL PRESENT BOTHKNEES
4 VIJAY 17 M 55399 2WEEKS NIL DYSURIA NIL ECOLI NIL NIL PRESENT BOTHKNEES,ANKLE,RT HIP
5 SUNDER 20 M 55412 1MONTH DIARRHOEA NIL NIL NIL NIL NIL PRESENT BOTH ANKLES,MIDTARSAL
6 BABU 20 M 55433 1MONTH DIARRHOEA NIL BRUCELLA NIL NIL NIL PRESENT BOT KNEES,HIP
7 SRINIVASAN 25 M 12670 1MONTH DIARRHOEA NIL SALMONELLA TYPHI NIL NIL NIL PRESENT BOTH KNEES,ANKLE,SOULDER
8 KAMUDAS 23 M 55573 2MONTHS NIL DYSURIA NIL NIL NIL NIL NIL ANKLE ,MIDTARSAL
9 DHARMARAJ 27 M 55663 10DAYS NIL NIL NIL NIL NIL KLEBSIELLA PRESENT KNEE,ANKLE,MIDTARSAL,SUBTALAR
10 KANNAN 46 M 55666 4WEEKS DIARRHOEA NIL SALMONELLA P. TYPHI NIL NIL NIL PRESENT BOTHKNEE,ANKLE,MIDTARSAL
11 GANESAN 23 M 54490 1MONTH NIL NIL BRUCELLA NIL NIL NIL NIL BOTH KNEES,ANKLES,MIDTASAL
12 VIJAYAN 52 M 55721 2WEEKS NIL DYSURIA NIL PROTEUSVULGARIS NIL NIL NIL BOTH ANKLE,MIDTARSAL,SUBTALAR
13 BASKARAN 19 M 55797 3WEEKS DIARRHOEA NIL NIL NIL SHIGELLA NIL PRESENT BOTH KNEES,ANKLE,
14 PETER 24 M 55821 4WEEKS DIARRHOEA NIL NIL NIL SALMONELLA NIL NIL BOTHANKLES,KNEES
15 SHANMUGAM 43 M 55918 2WEEKS DIARRHOEA NIL SALMONELLAP.TYPHI NIL NIL NIL PRESENT BOTHKNEES,ANKLE,SUBTALAR
16 NALLATHAMBI 44 M 55940 6WEEKS DIARRHOEA NIL SALMONELLAP.TYPHI NIL NIL NIL PRESENT BOTKNEES,ANKLES,
17 VINOTH 24 M 56303 2WEEKS NIL DYSURIA NIL NIL NIL NIL ABSENT BOTHKNEES,ANKLES
18 CHELLAPPAN 35 M 56591 4WEEKS NIL DYSURIA NIL NIL NIL NIL PRESENT BOTHKNEES,ANKLE
19 GANESH 25 M 56791 4WEEKS NIL DYSURIA NIL KLEBSEILLA NIL NIL PRESENT BOTHKNEES,ANKLES,MIDTARSAL
20 SETTU 24 M 56867 4WEEKS NIL DYSURIA NIL KLEBSEILLA NIL NIL PRESENT BOTHKNEE,ANKLE,MIDTARSAL
21 PARTHIBAN 24 M 56951 4WEEKS DIARRHOEA NIL SALMONELLAP.TYPHI NIL NIL NIL PRESENT BOTHKNEE,MIDTARSAL
22 SUBHASHINI 35 F 55704 6WEEKS NIL NIL NIL NIL NIL KLEBSIELLA PRESENT BOTHANKLE,KNEES,SHOULDER
23 MENAKA 35 F 55943 4WEEKS DIARRHOEA NIL SALMONELLAP.TYPHI NIL NIL NIL ABSENT BOTHANKLE,KNEES,
24 AMUTHA 33 F 55972 6WEEKS DIARRHOEA NIL NIL NIL NIL NIL PRESENT BOTHANKLES,KNEES
25 CHITRA 23 F 56084 6WEEKS NIL WHITEDISCHARGE NIL ECOLI NIL NIL ABSENT BOTHANKLES
26 SASIKALA 35 F 56147 6WEEKS DIARRHOEA NIL SALMONELLAP.TYPHI NIL NIL NIL PRESENT BOTHANKLES,ANKLES
27 SUGANYA 24 F 56340 4WEEKS NIL WHITEDISCHARGE NIL NIL NIL NIL ABSENT BOTHKNEES,ANKLES
28 GERISYAL 18 F 56637 6WEEKS DIARRHOEA NIL SALMONELLAP.TYPHI NIL NIL NIL PRESENT BOTHKNEES,ANKLES,MIDTARSAL
29 KOWSALYA 30 F 55557 6WEEKS NIL DYSURIA NIL NIL NIL NIL ABSENT BOTHANKLES
30 MANJULA 31 F 56129 6WEEKS NIL NIL BRUCELLA NIL NIL NIL PRESENT BOTHANKLES
31 SAMUNDEESWARI 26 F 56218 8WEEKS DIARRHOEA NIL NIL NIL NIL NIL ABSENT BOTHKNEES
32 KOMALA 31 F 56350 4WEEKS NIL WHITEDISCHARGE NIL NIL NIL NIL ABSENT BOTHKNEES,ANKLES,MIDTARSAL
33 MALLIGA 22 F 52316 6WEEKS DIARRHOEA NIL SALMONELLAP.TYPHI NIL NIL NIL PRESENT BOTHKNEE,ANKLES,HIP
34 SULTHAN 30 F 10134 2WEEKS NIL DYSURIA,WHITEDISCHARGE NIL NIL NIL NIL NIL BOTHKNEES,ANKLES
35 MERCY 50 F 10453 1WEEK NIL DYSURIA NIL KLEBSEILLA NIL NIL NIL BOTHKNEES
36 SARIKA 26 F 11263 2WEEKS NIL DYSURIA NIL CHLAMYDIA NIL NIL PRESENT RTKNEE,LFT ANKLE,
37 DEVI 35 F 10545 4WEEKS DIARRHOEA NIL SALMONELLA TYPHI NIL NIL NIL ABSENT BOTHKNEES
38 TAMILARASAN 40 M 11231 3WEEKS NIL DYSURIA NIL NIL NIL NIL ABSENT BOTHKNEES,ACHILLES
39 SUMATHY 30 F 12345 6WEEKS NIL WHITEDISCHARGE NIL NIL NIL NIL NIL BOTHKNEES,ANKLES
40 PARTHIBAN 24 M 10263 15DAYS NIL NIL NIL NIL NIL NIL NIL KNEE,ANKLE
41 PANCHANATHAN 45 M 35645 3WEEKS NIL DYSURIA NIL NIL NIL NIL NIL BOTHANKLES,ANKLES,MIDTARSAL
42 THILGAVATHY 35 F 406958 3WEEKS NIL DYSURIA NIL ECOLI NIL NIL PRESENT BOTHKNEES,ANKLES,MIDTARSAL
43 SUDHAKAR 31 M 11562 6WEEKS NIL DYSURIA,URETHRALDISCHARGE NIL ECOLI NIL NIL ABSENT BOTHKNEES
44 POORNIMA 26 F 55533 1WEEK DIARRHOEA NIL SALMONELLATYPHI NIL NIL NIL ABSENT BOTH KNEES,RTANKLE
45 VIJAYAN 35 M 55729 2WEEKS NIL DYSURIA NIL NIL NIL NIL ABSENT BOTHKNEES
46 IYYAPAN 24 M 54155 1WEEK DIARRHOEA NIL NIL NIL NIL NIL PRESENT BOTHKNEES,ANKLES,ELBOW
SEROLOGY STOOL CULTURE ARTHRITISGI SYMPTOMSI NO NAME AGE SEX RCCNO SYMPTOM DURATION GENITIURINARY
ACHILLES,PLANTAR FASCIA FEVER NIL NIL NORMAL NEGATIVE POSITIVE5.4OD NORMAL 17 8 5 NORMAL C.ReA
TIBIAL TUBERCLE FEVER PLAQUES OVERPALM ,SOLES NIL LVH,TRIVIAL AR NEGATIVE NEGATIVE NORMAL 10 0 0 NORMAL NORMAL
PLANTARFASCIA NIL NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 5 0 0 NORMAL NORMAL
PLANTAFASCITIS FEVER NIL NIL MVPPS NEGATIVE NEGATIVE NORMAL 11 3 0 NORMAL NORMAL
FLEXOR TENOSYNOVITIS ANKLE,DACTYLITIS FEVER NIL NIL NORMAL NEGATIVE POSITIVE5.4OD NORMAL 7 4 4 NORMAL C.ReA
PLANTARFASCIA, FEVER NIL NIL NORMAL POSITIVE NEGATIVE NORMAL 10 5 3 B/LSACROILITIS SPA
ACHILLES,PLANTAR FASCIA,ASIS,TIBIAL NIL NIL NIL NORMAL NEGATIVE POSITIVE4.4OD NORMAL 13 5 2 NORMAL C.ReA
ACHILLES,PLANTAR FASCIA STRICTRE URETHRA NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 7 4 0 NORMAL NORMAL
ACHILLES,PLANTAR FASCIA,ASIS,TIBIAL NIL NIL CONJUCTIVITIS NORMAL NEGATIVE POSITIVE4.2OD NORMAL 26 12 0 NORMAL NORMAL
ACHILLES,ASIS NIL NIL NIL NORMAL POSITIVE POSITIVE20.2OD NORMAL 22 6 4 B/LSACROILITIS SPA
DACTYLITIS NIL PAPULARLESION OVER TRUNK,ABDOMEN NIL NORMAL NEGATIVE NEGATIVE NORMAL 24 11 0 NORMAL NORMAL
PLANTARFASCIATIS NIL NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 20 6 0 NORMAL NORMAL
PLANTARFASCIA,TIBIALTUBERCLE NIL NIL NIL NORMAL POSITIVE NEGATIVE NORMAL 24 16 15 B/LSACROILITIS SPA
ACHILLES,DACTYLITIS FEVER NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 4 0 0 NORMAL NORMAL
PLANTARFASCIA NIL NIL CONJUCTIVITIS NORMAL NEGATIVE POSITIVE5.25OD NORMAL 20 6 5 B/LSACROILITIS SPA
PLANTARFASCIATIS,TIBIAL TUBERCE NIL NIL NIL NORMAL POSITIVE NEGATIVE NORMAL 10 8 8 B/LSACROILITIS SPA
ACHILLESTENDITIS FEVER NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 6 0 0 NORMAL NORMAL
PLANTARFASCIA,ACHILLES,TIBIALTUBERCLE NIL NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 6 0 0 NORMAL NORMAL
PLANTARFASCIA,ACHILLES,ASIS NIL N NIL NORMAL NEGATIVE POSITIVE34OD NORMAL 26 12 10 NORMAL C.ReA
PLANTARFASCITIS,DACTYLITIS 2TOE DM TINEAVERSICOLOR NIL NORMAL POSITIVE POSITIVE5.6OD NORMAL 16 12 8 B/LSACROILITIS SPA
PLANTARFASCIA,TIBIALTUBERCLE FEVER NIL NIL NORMAL POSITIVE POSITIVE4.2OD NORMAL 22 8 2 NORMAL NORMAL
DACTYLITIS,ACHILLESTENDINITIS FEVER NIL NIL NORMAL POSITIVE POSITIVE5.6OD NORMAL 34 14 4 B/LSACROILITIS SPA
PLANTARFASCIA FEVER NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 10 2 0 NORMAL NORMAL
ACHILLES,PLANTARFASCIA FEVER SEBORRHIC DERMATITIS NIL NORMAL NEGATIVE NEGATIVE NORMAL 8 5 0 NORMAL NORMAL
PLANTARFASCITIS, NIL NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 8 2 0 NORMAL NORMAL
PLANTARFASCIA,ACHILLES,TIBIALTUBERCLE FEVER NIL NIL NORMAL POSITIVE POSITIVE5.6OD NORMAL 18 8 6 B/LSACROILITIS SPA
PLANTARFASCIA NIL NIL NIL NORMAL NEGATIVE POSITIVE280D NORMAL 16 6 2 NORMAL C.ReA
PLANTARFASCIA,ACHILLES,TIBIALTUBERCLE,ASIS NIL NIL NIL NORMAL NEGATIVE POSITIVE9.2OD NORMAL 18 6 4 B/LSACROILITIS SPA
ACHILLESTENDITIS NIL NIL CONJUCTIVITIS NORMAL NEGATIVE NEGATIVE NORMAL 6 0 0 NORMAL NORMAL
PLANTARFASCITIS NIL NIL NIL NIL NEGATIVE NEGATIVE NORMAL 7 0 0 NORMAL NORMAL
ACHILLES,PLANTARFASCIA,LATERALEPICONDYLITIS NIL NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 6 0 0 NORMAL NORMAL
ACHILLES,PLANTARFASCIA NIL NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 12 0 0 NORMAL NORMAL
ASIS,ACHILLES,PLANTARFASCIA,TIBIALTUBERCLE NIL NIL NIL NORMAL POSITIVE POSITIVE12.4OD NORMAL 26 18 14 B/LSACROILITIS SPA
PLANTARFASCIA,ACHILLESTENDON NIL NIL NIL NORMAL NEGATIVE POSITIVE52OD NORMAL 18 5 5 NORMAL C.ReA
PLANTARFASCIA NIL NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 4 0 0 NORMAL NORMAL
B/L PLANTAR FASCITIS FEVER NORMAL NORMAL NORMAL POSITIVE POSITIVE 5.6OD NORMAL 16 7 3 B/LSACROILITIS SPA
ACHILLESTENDITIS FEVER NORMAL NORMAL NORMAL NEGATIVE POSITIVE4.2OD NORMAL 4 0 0 NORMAL NORMAL
PLANTARFASCITIS,ASIS FEVER NORMAL NORMAL NORMAL NEGATIVE POSITIVE4.2OD NORMAL 16 4 0 NORMAL NORMAL
ACHILLESTENDITIS NIL NORMAL NORMAL NORMAL NEGATIVE NEGATIVE NORMAL 6 0 0 NORMAL NORMAL
ACHILLES TENDINITIS FEVER NORMAL UVEITIS NOMAL NEGATIVE POSITIVE4.2OD NORMAL 23 14 3 NORMAL C.ReA
PLANTARFASCIATIS,ACHILESTENDINITIS NIL NORMAL NORMAL NORMAL NEGATIVE POSITIVE9.4OD NORMAL 13 8 3 NORMAL C.ReA
ACHILLESTENDITIS,TIBIALTUDERCLEENTHESITIS NIL NORMAL NORMAL NORMAL NEGATIVE POSITIVE40OD NORMAL 30 18 12 NORMAL C.ReA
LFTMIDDLEFINGERDACTYLITIS NIL BALANITIS CONJUCTIVITIS NORMAL POSITIVE POSITIVE29OD NORMAL 31 22 6 NORMAL C.ReA
PLANTARFASCITIS,ACHILLESTENDINITIS NIL NIL NIL NORMAL NEGATIVE NEGATIVE NORMAL 9 6 0 NORMAL NORMAL
PLANTARFASCITIS NIL NIL NIL NIL NEGATIVE NEGATIVE NORMAL 8 0 0 NORMAL NORMAL
DACYTILITIS FEVER NIL NIL AML,PMLRESTRITED NEGATIVE NEGATIVE NORMAL 12 4 0 NORMAL NORMAL
ENTHESITIS HLAB27 IL 17 CTPELVIS ONSET DAREA ONSET OUTCOMECT PELVIS1YRDAREA1YRECHO DAREA 6MONOPTHALSKINSYSTEMICSYMPTOMS
PATIENT CONSENT FORM 
Study Details: Clinical features and outcome of patients with 
Reactive Arthritis 
Study Centre: Department of Rheumatology, 
Rajiv Gandhi Government General Hospital, 
Madras Medical College, Chennai-600 003. 
Patient may check () these boxes 
I confirm that I have read and understood the Information Sheet for 
the above study. I have- had the opportunity to ask questions and all my 
questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time, without giving any reason, without my 
legal rights being affected. 
I understand that the Clinical study personnel, the Ethics Committee 
and the Regulatory Authorities will not need my permission to look at my 
health records both in respect to the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study. I 
agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or results 
that arise from this study. 
I agree to take part in the above study and to comply with the 
instructions given during the study and to faithfully co-operate with the 
study team, and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual 
symptoms. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
I hereby consent to participate in this study. 
 
Signature of Investigator Thumb Impression of Patient 
Patient Name/ Address 
Name of the Investigator 
Institution 
 INFORMATION SHEET 
 We are conducting a study on “Clinical features and 
outcome of patients with Reactive Arthritis” at 
Department of Rheumatology, Madras Medical College 
and Rajiv Gandhi Government General Hospital, Chennai-
600003. 
 The privacy of the patients in the research will be 
maintained throughout the study. In the event of any 
publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to 
decide whether to participate in this study or to withdraw 
at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you 
at the end of the study period or during the study if 
anything is found abnormal which may aid in the 
management or treatment. 
 
 
Signature of the Participant Signature of the Investigator 
Institution 
Date : 
MuhŒ¢á x¥òjš got«  
MuhŒ¢á jiy¥ò 
Éidah‰W« Ñœthj nehŒ 
MuhŒ¢á Ãiya« : Kl¡FthjÉaš Jiw, 
br‹id kU¤Jt¡ fšÿÇ k‰W« 
uhé› fhªâ muR bghJ kU¤Jtkid, br‹id.  
g¤F bgWtÇ‹ bga® : 
ghÈd« : 
g¤FbgwgtÇ‹ v© : 
g§F bgWgt® ïjid () F¿¡fî« 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu¤fŸ vd¡F És¡f¥g£lJ. 
v‹Dila rªnjf¤fis nf£fî«, mj‰fhd jFªj És¡f¤fis bgwî« 
thŒ¥gË¡f¥g£lJ. 
eh‹ ï›thŒÉš j‹Å¢irahfjh‹ g¤nf‰»nw‹. vªj 
fhuz¤âdhnyh vªj f£l¤âY« vªj r£l á¡fY¡F« c£glhkš eh‹ 
ï›thŒÉš ïUªJ Éy» bfhŸsyh« v‹W« m¿ªJ bfh©nl‹.  
ïªj MŒî r«gªjkhfnth, ïij rh®ªj nkY« MŒî nk‰bfhŸS« 
nghJ« ïªj MŒÉš g¤FbgW« kU¤Jt® v‹Dila kU¤Jt m¿¡iffis 
gh®¥gj‰F v‹ mDkâ njitÆšiy vd m¿ªJ bfhŸ»nw‹. eh‹ MŒÉš 
ïUªJ Éy»¡ bfh©lhY« ïJ bghUªJ« vd m¿»nw‹.  
ïªj MŒÉ‹ _y« »il¡F« jftšfisí«, gÇnrhjid Koîfisí« 
k‰W« á»¢ir bjhl®ghd jftšfisí« kU¤Jt® nk‰bfhŸS« MŒÉš 
ga‹gL¤â¡bfhŸsî« mij ãuRÇ¡fî« v‹ KG kdJl‹ r«kâ¡»‹nw‹.  
ïªj MŒÉš g¤F bfhŸs x¥ò¡bfhŸ»nw‹. vd¡F bfhL¡f¥g£l 
m¿îiufË‹go elªJ bfhŸtJl‹ ïªj MŒit nk‰bfhŸS« kU¤Jt 
mÂ¡F c©ikíl‹ ïU¥ng‹ v‹W cWâaË»nw‹. vdJ clš 
ey«ghâ¡f¥g£lhnyh mšyJ vâ®ghuhj tH¡fâ‰F khwhd nehŒ¡F¿ 
bj‹g£lhnyh clnd mij kU¤J mÂÆl« bjÇÉ¥ng‹ vd cWâ 
mË¡»nw‹. 
ïªj MŒÉš vd¡F kU¤Jt gÇnrhjid, ïu¤j¥ gÇnrhjid 
brŒJbfhŸs eh‹ KG kdJl‹ r«kâ¡»nw‹.  
 
g¤nf‰gtÇ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………… 
f£ilÉuš nuif 
g¤nf‰gtÇ‹ bga® k‰W« Éyhr« …………………………………………… 
MŒthsÇ‹ ifbah¥g« ……………….. ïl«…………….. njâ……………. 
MŒthsÇ‹ bga® ………………………………………… 
MuhŒ¢á jftš jhŸ 
br‹id ïuhé›fhªâ muR bghJ kU¤Jtid Kl¡FthjÉaš 
Jiw¡F tU« nehahËfËl« Éidah‰W« Ñœthj nehŒ g‰¿a 
MuhŒ¢á. 
Ú¤fS« MuhŒ¢áÆš g¤nf‰f ÉU«ò»nwh«. ïªj MuhŒ¢áÆš 
fâ®å¢R á»¢ir mË¤J áy áw¥ò gÇnrhjid¡F c£gL¤â mj‹ 
jftšfis MuhŒnth«. mjdhš j¤fË‹ nehÆ‹ MŒt¿¡ifnah, 
á»¢irnah ghâ¥ò V‰glhJ v‹gij bjÇÉ¤J¡ bfhŸ»nwh«. 
Koîfis mšyJ fU¤Jfis btËÆL«nghnjh mšyJ 
MuhŒ¢áÆ‹ nghnjh j¤fsJ bgaiunah mšyJ milahs¤fisnah 
btËÆlkh£nlh« v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«.  
ïªj MuhŒ¢áÆš g¤nf‰gJ j¤fSila ÉU¥g¤â‹ ngÇš jh‹ 
ïU¡»wJ. nkY« Ú¤fŸ vªneuK« ïªj MuhŒ¢áÆÈUªJ ã‹th¤fyh« 
v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj áw¥ò gÇnrhjidfË‹ Koîfisí« nehÆ‹ j‹ik g‰¿í« 
MuhŒ¢áÆ‹nghJ mšyJ MuhŒ¢áÆ‹ KoÉ‹ nghJ j¤fS¡F 
m¿É¥ngh« v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
 
 
-------------------------    ------------------------- 
MuhŒ¢áahs® ifbah¥g«   g¤nf‰ghs® ifbah¥g« 
njâ: 
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